Recursion Pharmaceuticals
AI-native drug discovery OS with industrial-scale automated labs and $500M+ in pharma partnerships
Gallery
5 items
About Recursion Pharmaceuticals
In my technical review of Recursion's drug discovery OS, its automated robotic wet-lab phenomics platforms capture petabytes of cellular microscopy images weekly, mapped across billions of biological relationships via AI. Industrial-scale biology screening replaces traditional trial-and-error discovery. The biological discovery pipeline operates on long-term clinical trial horizons, requiring massive ongoing capital and biopharma partnerships. Partnered with Bayer, Roche, and Genentech, it stands as a titan in industrial-scale computational biology.
Recursion Pharmaceuticals (NASDAQ: RXRX) is a clinical-stage TechBio company decoding biology to improve patient lives, powered by its Recursion OS — an AI-native, end-to-end drug discovery and development platform that integrates biology, chemistry, and clinical development into a single, continuously learning intelligence system. Founded in 2013 in Salt Lake City, Recursion operates industrial-scale automated biology and chemistry labs in both Salt Lake City and Milton Park, Oxfordshire, generating vast proprietary datasets that feed its AI models.
Recursion's most powerful differentiator is its ability to generate biology "maps" at unprecedented scale. Its Roche/Genentech Phenomaps project uses over 1 trillion internally manufactured neuronal cells to map biological relationships across neuroscience and oncology. Its Sanofi partnership has delivered $134M in milestone payments across 5 milestones. In total, Recursion has earned $500M+ in upfront and milestone payments from pharma partners, validating its platform's ability to generate drug candidates that large pharmaceutical companies want to advance. In 2024, Recursion acquired Exscientia to add AI-driven small molecule design capabilities to its platform.
On the clinical front, REC-4881 for familial adenomatous polyposis (FAP) showed 53% polyp burden reduction in Phase 2 — Recursion's first AI-enabled clinical proof of concept — with FDA registration discussions begun in H1 2026. Recursion is the choice platform for major pharma companies seeking AI-powered biology mapping and target discovery at industrial scale, and for investors seeking exposure to the most vertically integrated public TechBio company in the world.
Key Features
- Recursion OS — AI-native end-to-end drug discovery platform integrating biology, chemistry, and clinical development
- Industrial-scale automated labs in Salt Lake City and Oxford generating proprietary multimodal data
- REC-4881 for FAP — 53% polyp reduction in Phase 2, FDA registration discussions begun 2026
- REC-1245 (RBM39 degrader) in Phase 1/2 DAHLIA study for solid tumors
- REC-4539 (LSD1 inhibitor) — first patient dosed in Phase 1 ENLYGHT study 2026
- Sanofi partnership — $134M earned to date across 5 milestones
- Roche/Genentech Phenomaps — 1 trillion neuronal cells for neuroscience target discovery
- $500M+ in cumulative pharma partnership milestones earned to date
- Recursion Data — phenomics and biology maps licensed to external researchers and pharma
- NASDAQ: RXRX — founded 2013; $74.7M revenue in 2025; acquired Exscientia in 2024
Pros
- $500M+ in pharma partnership milestones — most validated AI drug platform by commercial revenue
- Recursion OS is the most vertically integrated AI drug discovery system — biology to clinic in one platform
- Industrial-scale automated labs generate data no other company can replicate
- Phase 2 FAP clinical proof of concept — 53% polyp reduction — FDA registration discussions began
- Roche/Genentech and Sanofi as partners — two of the world's top 5 pharma companies
- Exscientia acquisition in 2024 added cutting-edge small molecule AI design capabilities
- Cash runway guided into early 2028 — disciplined capital allocation
Cons
- Stock (RXRX) is below $5 — significant market skepticism on timeline to commercial drugs
- Operating cash burn of ~$390M in 2026 — needs continued capital or milestone payments
- Acquired Exscientia in 2024 — integration complexity and added operational overhead
- No approved drugs yet — clinical proof of concept still early stage
- Proprietary platform requires industrial-scale automation infrastructure that can't be self-built
Pricing & Plans
AI-enabled drug discovery and mapping (Recursion OS) — Custom biopharma enterprise partnership agreements only
Claim Verified Creator Badge
Are you the founder of Recursion Pharmaceuticals? Display this listing's verified badge on your website to show your customers that your product has been vetted and listed on AI Central Resources.
<a href="https://www.aicentralresources.com/tool/recursion-pharmaceuticals" target="_blank" rel="noopener"> <img src="https://www.aicentralresources.com/badges/featured-badge-dark.svg" alt="Featured on AICentralResources" width="200" height="54" style="border: none;" /> </a>
* Place this HTML snippet in your website's footer, landing page, or press section. This creates a search-friendly backlink directly to your verification page.
Connect with Recursion Pharmaceuticals
Frequently Asked Questions
The Recursion OS is Recursion's AI-native, end-to-end drug discovery operating system that integrates biology, chemistry, and clinical development into one continuous learning platform. It uses multimodal proprietary data (cellular imaging, genomics, chemistry), purpose-built AI models, and automated labs to generate, test, and refine drug candidates at industrial scale.
REC-4881 is Recursion's MEK1/2 inhibitor for familial adenomatous polyposis (FAP), which showed a 53% reduction in polyp burden in Phase 2 trials. Recursion began FDA engagement in H1 2026 to explore a potential registrational pathway, making it the company's most clinically advanced program.
Recursion has earned $500M+ in upfront and milestone payments from its partnerships, including $134M from Sanofi to date and large-scale neuroscience Phenomaps work with Roche and Genentech using over 1 trillion internally manufactured neuronal cells.
Recursion acquired Exscientia in late 2024 to combine Exscientia's AI-driven small molecule design capabilities with Recursion's massive biological dataset and automation infrastructure, creating the most comprehensive AI drug discovery platform in the industry.
Recursion (NASDAQ: RXRX) is publicly traded. As of mid-2026, RXRX stock trades below $5 per share. Total revenue for 2025 was $74.7M (up from $58.8M). The company has maintained cash runway guidance into early 2028.
Similar AI Tools to Recursion Pharmaceuticals
View all alternatives of Recursion Pharmaceuticals
Atomwise
Deep learning for structure-based drug discovery — AtomNet screens 16B+ compounds to find hits for any disease target
BenevolentAI
Clinical-stage AI drug discovery with integrated wet labs and AstraZeneca and Merck collaborations
Insilico Medicine
Generative AI drug discovery platform — from target identification to Phase 3 clinical trials with Pharma.AI
Schrödinger
Physics-based drug discovery with Bunsen AI co-scientist — trusted by 500+ pharma companies worldwide
Tempus AI
AI precision medicine platform — genomic profiling, clinical insights, and trial matching for personalized cancer care
OpenEvidence
AI clinical decision support free for verified physicians — 757K+ doctors, $12B valuation, peer-reviewed answers
Compared with Recursion Pharmaceuticals
Direct head-to-head feature matrices, pricing breakdowns, and real-world performance benchmarks
